Source: Pharmacy Times articles
Approximately 10% of patients with multiple myeloma have pathogenic germline variants, indicating a hereditary risk.
Read More
Recent Content
- Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis
- Correction: Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
- Genetic Study Sheds Light on Inherited Risk of Multiple Myeloma
- A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
- Expert Explains Early Signs, Treatment Advances and Care in Multiple Myeloma
- Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review
- Pharmacists Play an Essential Role in Bispecific Therapy for Multiple Myeloma
- Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma
- Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
- Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes